SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is rallying as the community intently focuses on whether the company will decline to match a recently deemed superior offer for Warner Bros. Discovery, with many investors hoping this avoids substantial debt and regulatory obstacles, potentially triggering further upside as the crucial decision looms.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance (PSKY) is heavily discussed as Warner Bros. Discovery (WBD) considers its revised, potentially superior takeover bid, prompting community debate over whether PSKY is making a transformative move or incurring excessive debt, and if Netflix will counter-bid or accept a breakup fee.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is sparking intense community debate following its latest earnings report, which featured robust revenue growth and a staggering $66.8 billion backlog but also widening net losses and an EPS miss. Investors are weighing the massive AI infrastructure demand and a new $8.5 billion Meta-backed loan against significant debt, cash burn, and execution challenges, with further clarity anticipated from the earnings call.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo is experiencing significant volatility following guidance that prioritizes user growth and AI innovation over immediate financial gains, alongside a $400M share buyback. This has ignited a fierce debate among investors regarding the company's long-term competitive moat against AI translation tools versus its potential to become an education super-app.

Block, Inc. engages in creating ecosystems for distinct customer audiences. It operates through the Square and Cash App segments. The Square segment provides payment services, software solutions, hardware, and financial services to sellers. The Cash App segment includes the financial tools available to individuals within the mobile Cash App, including peer-to-peer payments, bitcoin and stock investments. It also includes Cash App Card, which is linked to customer stored balances that customers can use to pay for purchases or withdraw funds from an ATM. The company was founded by Jack Patrick Dorsey and James Morgan McKelvey in February 2009 and is headquartered in Oakland, CA.

Block Inc - Ordinary Shares - Class A

Block Inc

Block Inc. is surging after announcing a significant workforce reduction and restructuring towards an "AI-first" strategy, coinciding with strong Q4 results. The market is cheering these aggressive cost-cutting measures, sparking community debate over the ethics of rewarding mass layoffs and their implications for the broader tech sector's efficiency through AI.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending as Netflix walks away from its acquisition bid after Paramount Skydance's offer was deemed superior, with the community largely praising Netflix's strategic move to collect a significant breakup fee, while WBD investors anticipate a higher payout from Paramount despite new debt concerns for the acquirer.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy Enterprises is trending following a substantial earnings miss on revenue and EPS, leading to a sharp stock decline and widespread community discussion about management's credibility and execution challenges. Despite calls of "worst CEO ever" and "major breach of trust" by many, some investors view the massive sell-off as an "oversold" opportunity, citing the company's zinc battery technology, growing backlog, and broader demand in the energy storage sector.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital Holdings is trending as a major strategic shift towards AI and high-performance computing data centers, driven by new partnerships and acquisitions, is generating intense community discussion and speculation about a significant short squeeze, largely overshadowing recent disappointing financial results.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending due to a dual financing announcement, including a non-dilutive royalty deal for its prostate cancer candidate and a concurrent public offering, which has sparked intense community debate over dilution and management's long-term commercialization strategy. Bulls view the capital raise as crucial validation and runway for its promising oncology pipeline, while bears express strong concerns about shareholder value and the impact on a potential "go it alone" approach.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending after its latest earnings report revealed record annual revenue, a GAAP profit, and robust 2026 guidance, sparking strong bullish sentiment among investors. The community is actively debating the potential for a short squeeze given high short interest, though some members remain cautious about the company's long-term profitability trajectory.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Top Research Reports for Meta, Netflix & Pfizer

Meta Platforms, Netflix and Pfizer lead fresh research as AI bets, bold 2030 goals and patent cliffs shape their outlooks.

Promising Pharmaceutical Stocks To Follow Now - February 26th

Eli Lilly and Company, Avidity Biosciences, Novo Nordisk A/S, AbbVie, Gilead Sciences, Abbott Laboratories, and Pfizer are the seven Pharmaceutical stocks to watch today, according to MarketBeat's...

Thornburg Investment Management Inc. Sells 9,009,301 Shares of Pfizer Inc. $PFE

Thornburg Investment Management Inc. lowered its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 86.1% in the third quarter, according to its most recent disclosure with the SEC. The...

Mitsubishi UFJ Asset Management Co. Ltd. Increases Holdings in Pfizer Inc. $PFE

Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 4.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange...

Pfizer (NYSE:PFE) Upgraded to Strong Sell at Royal Bank Of Canada

Royal Bank Of Canada upgraded Pfizer to a "strong sell" rating in a report on Tuesday...

Pfizer (NYSE:PFE) Upgraded by Zacks Research to Hold Rating

Zacks Research raised shares of Pfizer from a "strong sell" rating to a "hold" rating in a research note on Tuesday...

<ul class="summary-bullets"><li>TD Cowen and BofA both raised price targets following the Pfizer partnership but the latter maintained a cautious stance.</li><li>The Matrix-M agreement brought a $30 million upfront payment and potential $500 million in milestones.</li><li>Activist pressure from Shah Capital continues to be an overhang, with the investor pushing for strategic alternatives.</li></ul>Novavax, Inc. (NVAX) shares rose nearly 2% overnight ahead of the company’s fourth-quarter (Q4) earnings due Thursday, as fresh Pfizer partnership tailwinds lifted sentiment, even as analysts warned the stock could face downside.<a href="https://stocktwits.com/symbol/NVAX">NVAX stock</a> climbed 0.7% in Monday’s regular session to $9.53 and added another 0.8% in after-hours trading.&nbsp;<h2 class="st-heading-2">Pfizer Deal Shapes Analyst Views</h2>TD Cowen raised its price target on Novavax to $8 from $7, implying a 16% downside from current levels, while maintaining a 'Hold' rating. The brokerage incorporated Sanofi’s reported Q4 Nuvaxovid sales of 9 million euros ($10.6 million) and the company’s Matrix-M licensing deal with Pfizer, which includes high mid-single-digit (MSD) royalty payments, into its outlook.Last month, Bank of America Securities (BofA) also raised its price target to $7 from $6 following the Pfizer partnership announcement, but reiterated an 'Underperform' rating. “While the firm thinks the agreement is a positive sign for interest in the technology and the upfront cash is a plus, it sees the cadence of development as an outstanding question,” BofA said.Novavax entered into a non-exclusive licensing agreement with Pfizer last month for its Matrix-M adjuvant to be used in vaccine products across up to two disease areas. Under the deal, Novavax received a $30 million upfront payment and is eligible for up to $500 million in development and sales milestones, along with tiered, high mid-single-digit royalty payments on Pfizer products that incorporate Matrix-M. Pfizer will lead development and commercialization, while Novavax will supply the adjuvant.<h2 class="st-heading-2">Wall Street Expects NVAX Q4 Losses To Narrow</h2>According to Koyfin data, analyst price targets for Novavax range from $6 to $25, with a 12-month average target of $13. This suggests a potential upside of about 36% from the stock’s last close. Analysts have also assigned a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mrna-vs-nvax-which-vaccine-stock-is-wall-street-more-bullish-on-right-now/cmUzkZbR4QI">greater upside</a> to Novavax than to rival Moderna, based on consensus price targets.Consensus ratings lean toward 'Buy', with five analysts assigning a 'Buy' rating, one a 'Hold', one a 'Sell', and two a 'Strong Sell', based on coverage from nine analysts.Koyfin estimates project revenue at $89.86 million, up from $70.44 million in the previous quarter, representing nearly 28% growth. Meanwhile, losses are expected to narrow significantly. Earnings before interest, tax, depreciation, and amortization (EBITDA)&nbsp;are projected at a loss of $69.59 million compared with a loss of $171.43 million last quarter.&nbsp;Earnings before interest and taxes (EBIT)&nbsp;are forecast at a loss of $70.74 million versus a loss of $178.02 million earlier. GAAP loss per share (EPS) is expected at $0.49 compared with a loss of $1.25 in the last quarter.<h2 class="st-heading-2">Activist Push Raises Governance Pressure</h2>Sentiment toward Novavax has also turned more cautious after activist investor&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-stock-faces-retail-backlash-as-shah-capital-warns-of-proxy-fight-and-presses-for-a-sale/cLPBFk7REdt">Shah Capital</a> intensified pressure on the company late last year. In November, the fund, Novavax’s second-largest shareholder, warned it could pursue a proxy fight within four months if the board failed to act, while pushing for a review of strategic alternatives, including a potential sale.&nbsp;Shah Capital raised its stake to about 8.3% but flagged disappointment with the commercial performance of the company’s Covid-19 vaccine, citing a sharp gap in seasonal uptake versus competitors. The fund said it remained supportive of the underlying science but questioned execution, urging the board to appoint an investment bank to evaluate options.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for NVAX was ‘bearish’ amid ‘normal’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/nvax_ss_png_1e291e7db2.webp" alt="nvax ss.png" width="971" height="142"><figcaption>NVAX sentiment and message volume as of February 26 | Source: Stocktwits</figcaption></figure>One bullish user expressed optimism, noting “The specific disease areas Pfizer has selected for Matrix-M remain undisclosed, though&nbsp; the first field has already been chosen with an option to designate a second.”<stembedurl>https://stocktwits.com/ejaXstoXX/message/645927184</stembedurl>Another user pointed to a rivalry between Merck and Bristol Myers Squibb, suggesting that Novavax’s Matrix-M could create a “competitive advantage” with differentiation.<stembedurl>https://stocktwits.com/Trissy/message/645942169</stembedurl>NVAX stock has jumped 42% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The transaction will provide Novavax with $190 million in cash by 2024 and an additional $10 million in 2025.

NVAX Stock Rises Overnight Ahead Of Q4 Print With Pfizer Tailwinds — Analyst Warns Of 20% Crash

Koyfin analysts expect revenue to grow nearly 28% from the last quarter and forecast losses to narrow significantly.

Equity

Best Pharmaceutical Stocks To Watch Now - February 25th

Novo Nordisk A/S, Eli Lilly and Company, Jazz Pharmaceuticals, AbbVie, Pfizer, Gilead Sciences, and Bristol Myers Squibb are the seven Pharmaceutical stocks to watch today, according to MarketBeat's...

ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced positive 12-month interim efficacy and tolerability data from the...

Can J&J Sustain Its Double-Digit Oncology Growth Streak?

JNJ's oncology sales surged in 2025 as Darzalex and new drugs powered growth. With a $50B target by 2030, can its cancer momentum last?

This account has been verified as an official PFE representative.

Verified Account

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

PFE
Pfizer Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PFE News

PFEPfizer Inc